41,80 €
2,70 %vorgestern
L&S, 23. Februar, 22:55 Uhr
ISIN
US76243J1051
Symbol
RYTM
Berichte
Sektor
Industrie

Rhythm Pharmaceuticals, Inc. Aktie News

Neutral
Seeking Alpha
3 Tage alt
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2023 Earnings Call Transcript
Neutral
GlobeNewsWire
3 Tage alt
-- Supplemental cohort of 12 Japanese patients to be added to global Phase 3 hypothalamic obesity trial, with dosing expected to begin in third quarter of 2024 -- -- Significant unmet need with 5,000 to 8,000 patients with hypothalamic obesity estimated to be living in Japan --
Neutral
GlobeNewsWire
3 Tage alt
-- Fourth quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $24.2 million -- -- Enrollment completed in 120-patient, pivotal cohort of Phase 3 setmelanotide trial in hypothalamic obesity; top-line data on track for 1H2025 --
Neutral
GlobeNewsWire
17 Tage alt
BOSTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on February 2, 2024, the Compensation Committee of Rhythm's board of directors granted inducement equity grants covering an aggregate of ...
Neutral
GlobeNewsWire
25 Tage alt
Company to participate in fireside chats at Guggenheim's 6th Annual Biotechnology Conference on Feb. 7 and TD Cowen 44th Annual Health Care Conference on March 5 Company to participate in fireside chats at Guggenheim's 6th Annual Biotechnology Conference on Feb. 7 and TD Cowen 44th Annual Health Care Conference on March 5
Positiv
MarketBeat
etwa ein Monat alt
Clinical weight-loss medications have been making headlines. GLP-1 drugs like Novo Nordisk A/S NYSE: NVO owned Ozempic and Wegovy and Eli Lilly and Co. NYSE: LLY owned Mounjaro and Zepbound continue to see demand outstrip supply.
Neutral
GlobeNewsWire
etwa ein Monat alt
BOSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on January 9, 2023, the Compensation Committee of Rhythm's board of directors granted inducement equity grants covering an aggregate of 1...
Neutral
GlobeNewsWire
etwa 2 Monate alt
-- LB54640 has shown targeted effect on MC4 receptor without hyperpigmentation -- -- Rhythm to advance LB54640 in two Phase 2 clinical trials --
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen